Peer-reviewed veterinary case report
One-year follow-up of dogs treated with marbofloxacin
By Rougier, Sandrine et al.·Published in Veterinary parasitology·2012·Vé, France·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: One-year clinical and parasitological follow-up of dogs treated with marbofloxacin for canine leishmaniosis.
- Species:
- dog
Plain-English summary
A group of 74 dogs showing signs of canine leishmaniosis (a disease caused by parasites) were treated with marbofloxacin, an antibiotic, for 28 days. After treatment, about 69% of the dogs showed improvement within 51 days, with some even appearing clinically cured after three months. However, more than half of the dogs experienced a relapse about five and a half months later, indicating that while marbofloxacin can help manage the disease, it may not completely eliminate the parasites. Overall, the treatment showed promise, but ongoing monitoring is important for these dogs.
People also search for: dog leishmaniosis treatment · marbofloxacin for dogs · canine leishmaniosis symptoms · dog relapse after leishmaniosis treatment
Abstract
The purpose of this international, multicentric, and non-comparative field trial was to obtain complementary data on long-term clinical and parasitological follow-up of dogs treated with marbofloxacin for canine leishmaniosis (CanL). Seventy-four dogs with clinical signs of CanL and without severe renal failure were recruited in France, Spain and Italy, and 61 of them were part of the analysis. Each dog was treated with palatable tablets of marbofloxacin at 2 mg/kg once a day for 28 days. A clinical and parasitological follow-up was performed regularly up to 12 months. Efficacy was demonstrated in 42 dogs (68.9%), within 51 days (mean value), 10 of them (23.8%) being clinically cured after 3 months. A decrease of 61% in the sum of clinical scores was observed after 3 months. Haemato-biochemical parameters improved in general, supporting the observed clinical efficacy. Relapse was observed in 20/38 dogs (52.6%) approximately 5.5 months after treatment completion. The blood parasite load generally developed in conformity with the clinical outcome, even if exceptions were not rare. Lymph nodes remained positive by culture or PCR for a long time, even in dogs for which a good clinical response was observed. Despite the incomplete parasite clearance, as is also the case with other anti-leishmanial drugs, these results nevertheless confirm the relevance of marbofloxacin as a CanL treatment.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22130335/